Literature DB >> 18379151

Development of tumor-induced osteomalacia in a subcutaneous tumor, defined by venous blood sampling of fibroblast growth factor-23.

Eriko Ogura1, Kazunori Kageyama, Seiji Fukumoto, Norito Yagihashi, Yoshiko Fukuda, Toru Kikuchi, Mitsuo Masuda, Toshihiro Suda.   

Abstract

A 25-year-old man with severe lumbago was referred to our department for further evaluation. Serum phosphate and TmP/GFR levels were decreased. Physical examination revealed an elastic tumor in the instep of the right foot, which the patient reported having since the age of 10 years. He had no symptoms of osteomalacia at that time. Within the recent years, the tumor had grown in size and the patient developed lumbago. To examine the existence of a fibroblast growth factor-23 (FGF-23)-producing tumor, venous blood was collected from four main veins. FGF-23 levels were significantly increased in the right femoral vein, compared with other veins. After the resection of the tumor, the histopathology was consistent with a phosphaturic mesenchymal tumor (mixed connective tissue variant). Taken together, these results indicated that the development of osteomalacia in this patient was associated with the production of FGF-23 in the subcutaneous tumor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18379151     DOI: 10.2169/internalmedicine.47.0761

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  9 in total

1.  Tumor-Induced Osteomalacia.

Authors:  Rajiv Kumar; Andrew L Folpe; Brian P Mullan
Journal:  Transl Endocrinol Metab       Date:  2015

Review 2.  Tumor-induced osteomalacia.

Authors:  William H Chong; Alfredo A Molinolo; Clara C Chen; Michael T Collins
Journal:  Endocr Relat Cancer       Date:  2011-06-08       Impact factor: 5.678

3.  Selective venous catheterization for the localization of phosphaturic mesenchymal tumors.

Authors:  Panagiota Andreopoulou; Claudia E Dumitrescu; Marilyn H Kelly; Beth A Brillante; Carolee M Cutler Peck; Felasfa M Wodajo; Richard Chang; Michael T Collins
Journal:  J Bone Miner Res       Date:  2011-06       Impact factor: 6.741

Review 4.  Tumor-induced osteomalacia with elevated fibroblast growth factor 23: a case of phosphaturic mesenchymal tumor mixed with connective tissue variants and review of the literature.

Authors:  Fang-Ke Hu; Fang Yuan; Cheng-Ying Jiang; Da-Wei Lv; Bei-Bei Mao; Qiang Zhang; Zeng-Qiang Yuan; Yan Wang
Journal:  Chin J Cancer       Date:  2011-11

5.  Effective localization in tumor-induced osteomalacia using 68Ga-DOTATOC-PET/CT, venous sampling and 3T-MRI.

Authors:  Shintaro Kawai; Hiroyuki Ariyasu; Yasushi Furukawa; Reika Yamamoto; Shinsuke Uraki; Ken Takeshima; Kenji Warigaya; Yuji Nakamoto; Takashi Akamizu
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2017-04-19

6.  Association of serum levels of FGF23 and α-Klotho with glomerular filtration rate and proteinuria among cardiac patients.

Authors:  Michishige Ozeki; Shu-ichi Fujita; Shun Kizawa; Hideaki Morita; Koichi Sohmiya; Masaaki Hoshiga; Nobukazu Ishizaka
Journal:  BMC Nephrol       Date:  2014-09-08       Impact factor: 2.388

Review 7.  Diagnostic Modalities for FGF23-Producing Tumors in Patients with Tumor-Induced Osteomalacia.

Authors:  Seiji Fukumoto
Journal:  Endocrinol Metab (Seoul)       Date:  2014-06

Review 8.  Tumour-induced osteomalacia: a literature review and a case report.

Authors:  Jolanta Dadoniene; Marius Miglinas; Dalia Miltiniene; Donatas Vajauskas; Dmitrij Seinin; Petras Butenas; Tomas Kacergius
Journal:  World J Surg Oncol       Date:  2016-01-08       Impact factor: 2.754

9.  Selective blood sampling for FGF-23 in tumor-induced osteomalacia.

Authors:  Hans-Christof Schober; Christian Kneitz; Franziska Fieber; Kathrin Hesse; Henry Schroeder
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2017-10-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.